Bifogade filer
Kurs
+3,03%
Likviditet
2,27 MSEK
Prenumeration
Kalender
| Est. tid* | ||
| 2026-02-12 | 08:30 | Bokslutskommuniké 2025 |
| 2025-10-21 | - | Kvartalsrapport 2025-Q3 |
| 2025-07-18 | - | Kvartalsrapport 2025-Q2 |
| 2025-05-09 | - | X-dag ordinarie utdelning CRAD B 0.00 SEK |
| 2025-05-08 | - | Årsstämma |
| 2025-05-07 | - | Kvartalsrapport 2025-Q1 |
| 2025-02-07 | - | Bokslutskommuniké 2024 |
| 2024-10-23 | - | Kvartalsrapport 2024-Q3 |
| 2024-07-18 | - | Kvartalsrapport 2024-Q2 |
| 2024-05-16 | - | X-dag ordinarie utdelning CRAD B 0.00 SEK |
| 2024-05-15 | - | Årsstämma |
| 2024-05-14 | - | Kvartalsrapport 2024-Q1 |
| 2024-02-08 | - | Bokslutskommuniké 2023 |
| 2023-10-27 | - | Kvartalsrapport 2023-Q3 |
| 2023-07-20 | - | Kvartalsrapport 2023-Q2 |
| 2023-05-08 | - | X-dag ordinarie utdelning CRAD B 0.00 SEK |
| 2023-05-05 | - | Årsstämma |
| 2023-05-05 | - | Kvartalsrapport 2023-Q1 |
| 2023-01-26 | - | Bokslutskommuniké 2022 |
| 2022-10-28 | - | Kvartalsrapport 2022-Q3 |
| 2022-07-21 | - | Kvartalsrapport 2022-Q2 |
| 2022-05-09 | - | X-dag ordinarie utdelning CRAD B 0.00 SEK |
| 2022-05-06 | - | Årsstämma |
| 2022-05-06 | - | Kvartalsrapport 2022-Q1 |
| 2022-01-27 | - | Bokslutskommuniké 2021 |
| 2021-10-28 | - | Kvartalsrapport 2021-Q3 |
| 2021-07-29 | - | Kvartalsrapport 2021-Q2 |
| 2021-05-10 | - | X-dag ordinarie utdelning CRAD B 0.00 SEK |
| 2021-05-07 | - | Årsstämma |
| 2021-05-07 | - | Kvartalsrapport 2021-Q1 |
| 2021-01-28 | - | Bokslutskommuniké 2020 |
| 2020-10-22 | - | Kvartalsrapport 2020-Q3 |
| 2020-07-31 | - | Kvartalsrapport 2020-Q2 |
| 2020-05-11 | - | X-dag ordinarie utdelning CRAD B 0.00 SEK |
| 2020-05-08 | - | Årsstämma |
| 2020-05-06 | - | Kvartalsrapport 2020-Q1 |
| 2020-01-31 | - | Bokslutskommuniké 2019 |
| 2019-12-17 | - | Extra Bolagsstämma 2019 |
| 2019-10-25 | - | Kvartalsrapport 2019-Q3 |
| 2019-08-30 | - | Kvartalsrapport 2019-Q2 |
| 2019-05-09 | - | X-dag ordinarie utdelning CRAD B 0.00 SEK |
| 2019-05-08 | - | Årsstämma |
| 2019-05-08 | - | Kvartalsrapport 2019-Q1 |
| 2019-02-08 | - | Bokslutskommuniké 2018 |
| 2018-10-26 | - | Kvartalsrapport 2018-Q3 |
| 2018-08-17 | - | Kvartalsrapport 2018-Q2 |
| 2018-05-31 | - | Årsstämma |
| 2018-05-18 | - | X-dag ordinarie utdelning CRAD B 0.00 SEK |
| 2018-04-26 | - | Kvartalsrapport 2018-Q1 |
| 2018-01-31 | - | Bokslutskommuniké 2017 |
| 2017-10-27 | - | Kvartalsrapport 2017-Q3 |
| 2017-08-16 | - | Kvartalsrapport 2017-Q2 |
| 2017-05-02 | - | X-dag ordinarie utdelning CRAD B 0.00 SEK |
| 2017-04-28 | - | Årsstämma |
| 2017-04-28 | - | Kvartalsrapport 2017-Q1 |
| 2017-02-13 | - | Bokslutskommuniké 2016 |
| 2016-11-17 | - | Extra Bolagsstämma 2016 |
| 2016-11-14 | - | Kvartalsrapport 2016-Q3 |
| 2016-08-24 | - | Kvartalsrapport 2016-Q2 |
| 2016-05-09 | - | Kvartalsrapport 2016-Q1 |
| 2016-04-15 | - | X-dag ordinarie utdelning CRAD B 0.00 SEK |
| 2016-04-14 | - | Årsstämma |
| 2016-02-08 | - | Bokslutskommuniké 2015 |
| 2015-11-06 | - | Kvartalsrapport 2015-Q3 |
| 2015-08-14 | - | Kvartalsrapport 2015-Q2 |
| 2015-05-08 | - | Kvartalsrapport 2015-Q1 |
| 2015-04-17 | - | X-dag ordinarie utdelning CRAD B 0.00 SEK |
| 2015-04-16 | - | Årsstämma |
| 2015-01-30 | - | Bokslutskommuniké 2014 |
| 2014-11-07 | - | Analytiker möte 2014 |
| 2014-11-07 | - | Kvartalsrapport 2014-Q3 |
| 2014-08-15 | - | Kvartalsrapport 2014-Q2 |
| 2014-05-16 | - | Kvartalsrapport 2014-Q1 |
| 2014-04-17 | - | X-dag ordinarie utdelning CRAD B 0.00 SEK |
| 2014-04-16 | - | Årsstämma |
| 2014-02-17 | - | Bokslutskommuniké 2013 |
| 2013-11-28 | - | Kvartalsrapport 2013-Q3 |
| 2013-11-01 | - | Analytiker möte 2013 |
| 2013-10-30 | - | Extra Bolagsstämma 2013 |
| 2013-09-02 | - | 15-7 2013 |
| 2013-08-30 | - | Kvartalsrapport 2013-Q2 |
| 2013-06-03 | - | X-dag ordinarie utdelning CRAD B 0.00 SEK |
| 2013-05-31 | - | Årsstämma |
| 2013-05-29 | - | Kvartalsrapport 2013-Q1 |
| 2013-02-26 | - | Bokslutskommuniké 2012 |
| 2012-12-04 | - | Extra Bolagsstämma 2012 |
| 2012-11-28 | - | Kvartalsrapport 2012-Q3 |
| 2012-09-04 | - | Kvartalsrapport 2012-Q2 |
| 2012-06-04 | - | X-dag ordinarie utdelning CRAD B 0.00 SEK |
| 2012-06-01 | - | Årsstämma |
| 2012-05-24 | - | Kvartalsrapport 2012-Q1 |
| 2012-02-24 | - | Bokslutskommuniké 2011 |
| 2011-11-25 | - | Kvartalsrapport 2011-Q3 |
| 2011-08-26 | - | Kvartalsrapport 2011-Q2 |
| 2011-05-26 | - | X-dag ordinarie utdelning CRAD B 0.00 SEK |
| 2011-05-25 | - | Årsstämma |
| 2011-05-24 | - | Kvartalsrapport 2011-Q1 |
| 2011-02-11 | - | Bokslutskommuniké 2010 |
| 2010-06-02 | - | X-dag ordinarie utdelning CRAD B 0.00 SEK |
| 2010-06-01 | - | Årsstämma |
| 2010-05-28 | - | Kvartalsrapport 2010-Q1 |
| 2009-11-27 | - | Kvartalsrapport 2009-Q3 |
Beskrivning
| Land | Sverige |
|---|---|
| Lista | Small Cap Stockholm |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
C-RAD AB (publ) (“C-RAD”), a global leader in surface guided radiation therapy (SGRT), announces today that the Board of Directors, supported by the authorization from the 2025 Annual General Meeting, has decided to repurchase a maximum of 597,000 class B shares for an amount of up to SEK 20 million during the period up to the 2026 Annual General Meeting (the “Repurchase Program”). The purpose of the Repurchase Program is to optimize C-RAD’s capital structure by reducing the share capital by canceling repurchased class B shares and consequently the Board of Directors of C-RAD intends to propose to the 2026 Annual General Meeting to resolve on this.
The Repurchase Program will be implemented by Pareto Securities AB on behalf of C-RAD. Pareto Securities AB will make its trading decisions regarding the B shares independently of and without influence from C-RAD and otherwise in accordance with the applicable rules and regulations of Nasdaq's rules and regulations for issuers of shares on the main market (the "Rules"), Regulation (EU) No 596/2014 of the European Parliament and of the Council on market abuse ("MAR") and Commission Delegated Regulation (EU) 2016/1052 (the "Safe Harbour Regulation").
The repurchase program is subject to the following conditions:
- Repurchases may be made on one or more occasions during the period until the 2026 Annual General Meeting. During this period, C-RAD may repurchase a maximum of 597,000 of its own class B shares for an amount of up to 20 million SEK.
- Repurchases shall be made on Nasdaq Stockholm and in accordance with the Rules and Regulations, MAR and the Safe Harbour Regulation.
- Repurchases on Nasdaq Stockholm shall be made at a price per share within the price range applicable at any given time, which is the interval between the highest bid price and the lowest ask price, and in addition, the price restrictions in the Safe Harbour Regulation shall be observed.
- Repurchases may only be made in compliance with the quantity restrictions for the purchase of own shares specified in the Rules and in the Safe Harbour Regulation.
- In accordance with the authorization from the 2025 Annual General Meeting, C-RAD's holding of own shares may not exceed 10 percent of all outstanding shares in C-RAD.
- Payment for the repurchase of own class B shares shall be made in cash.
The purpose of the Repurchase Program is to optimize C-RAD's capital structure by reducing the share capital with the cancellation of repurchased class B shares, and consequently the Board of Directors of C-RAD intends to propose to the 2026 Annual General Meeting to resolve on this. As previously communicated, C-RAD's financial targets, in the medium term, are for average organic growth to exceed 10 percent and the operating margin (EBIT margin) to reach 25 percent. At least 30 percent of the net profit shall be returned to shareholders.
The total number of outstanding shares is 33,766,935, divided into 862,887 class A shares and 32,904,048 class B shares. C-RAD currently holds 188,500 of its own class B shares, corresponding to approximately 0.6 percent of the total number of its own shares in C-RAD.
For further information:
Linda Frölén, acting CEO, +46 (0) 70 303 3253, investors@c-rad.com
About C-RAD
C-RAD develops surface-guided imaging solutions for radiation therapy to allow highly accurate dose delivery to the tumor, and at the same time, to protect healthy tissue from unwanted exposure. Using high-speed 3D cameras combined with augmented reality, C-RAD supports the initial patient setup process and monitors the patient's motion during treatment to ensure high confidence, an efficient workflow, and improved accuracy. C-RAD monitors the patient's motion without the use of tattoos or additional imaging dose, to deliver the highest level of patient safety and comfort.
C-RAD AB is listed on NASDAQ Stockholm.
For more information on C-RAD, please visit http://www.c-rad.com